ArticleDiscover oncology2026
Epidemiology and prognostic factors of Hürthle-oncocytic cell carcinoma of the thyroid.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Distinct ALK Expression Patterns Are Associated with Canonical and Noncanonical STRN::ALK Transcript Architectures in Oncocytic Thyroid Neoplasms.Endocrine pathology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHürthle cell carcinoma (HCC) -recently known as oncocytic carcinoma- is a rare type of differentiated thyroid cancer that presents a diagnostic and therapeutic challenge because of its morphological heterogeneity and uncertain biological behavior.
methodsThis retrospective single-center cohort study included all the patients with HCC who underwent surgical treatment in our center from January 2009 to May 2024. The epidemiological, clinical, and oncological data of the included patients were analyzed.
resultsThis study included nineteen cases of HCC (9 males and 10 females). The average age at diagnosis was 54.8 ± 12.2 years. Preoperative fine needle aspiration cytology (FNAC) classified 2 tumors as Bethesda I, 7 as Bethesda III, 6 as Bethesda IV, and 4 as Bethesda V. A variety of surgical procedures were used, including hemithyroidectomy in 3 patients and total thyroidectomy in 12 patients. Two patients underwent neck dissection. The median tumor size was 6.7 cm. Pathological evaluation identified 9 patients with unifocal lesions and 10 with multifocal lesions. Only one patient showed positive lymph node involvement. The median times to death, distant metastasis, and locoregional recurrence were 4, 13, and 6 years, respectively. For locoregional recurrence, the restricted mean survival time (RMST) at five years was 4.4 years (95% CI 3.9-4.9), 4.6 years (95% CI 4.1-5.0) for distant metastasis, and 4.1 years (95% CI 3.6-4.5) for overall survival. There was a trend towards worse prognosis in females, younger age, and those with primary surgery outside the center. These differences did not achieve statistical significance, at least partly due to the small sample size.
conclusionDiagnosing HCC remains challenging due to its overlapping features with other thyroid conditions, making fine-needle aspiration cytology less definitive. Surgical treatment remains the preferred therapeutic option. Age, gender, and the volume of the surgical center for the initial procedure can influence patient outcomes, particularly recurrence and survival rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.